Latest News

The FDA today issued a Complete Response Letter for Cingulate’s CTx-1301 for ADHD, citing CMC-related requests and no current safety or efficacy concerns.

FDA approved ensitrelvir for COVID-19 postexposure prophylaxis in adults and adolescents aged 12 years and older after exposure.

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Kohli discusses the FDA approval of baxdrostat (Baxfendy), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

A validated AI phenotyping tool identified chronic long COVID burden missed by ICD surveillance in nearly 460,000 COVID-19 patients.